Relugolix
- TRADE NAME: Orgovyx (Myovant Sciences)
- INDICATIONS: Treatment of adult patients with advanced prostate cancer.
- CLASS: Gonadotropin-releasing hormone (GnRH) antagonist
- HALF-LIFE: 25 hours
FDA APPROVAL DATE: 12/18/2020
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:CYP3A inducers, Erythromycin, P-gp inhibitors, Rifampin
Relugolix can cause fetal harm. Advise males with female partners of reproductive potential to use effective contraception.
Androgen deprivation therapy, such as relugolox may prolong the QT/QTc interval.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric